ISM5411 not checked

InSilico Medicine Hong Kong Limited

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
1 active
2 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“Dosage Form: Tablet ; Frequency of administration: Orally QD.”In the company’s words, NCT07265570 on ClinicalTrials.gov
Tested for
Ulcerative Colitis
Main trialPhase 2
“This is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics and clinical efficacy of ISM5411 in adult patients with active ulcerative colitis.”In the company’s words, NCT07265570 on ClinicalTrials.gov
Other names
Garutadustat

Other drugs for Ulcerative Colitis

All 79 drugs for Ulcerative Colitis

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials2

TrialPhaseCompletesWhat it tests
Phase 2Recruiting 15 Aug 2027 Study Evaluating ISM5411 Administered Orally to Subjects With Active Ulcerative Colitis (BETHESDA)
Phase 1Completed 4 Sep 2024 Study Evaluating ISM5411 Administered Orally to Healthy Volunteers
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow ISM5411

Following is part of Solo: you see every change to ISM5411 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in